Profile
Robert Freisen worked as the Head of Preclinical & Early Clinical Development at MorphoSys AG.
He was the Vice President of Preclinical & Clinical Research at Janssen Biotherapeutics from 2008 to 2014.
He served as the Senior VP of Science & Early Development at ProQR Therapeutics NV from 2016 to 2018.
In 2018, he became the Chief Scientific Officer at Ablynx NV.
Dr. Freisen holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from the University of Utrecht.
Former positions of Robert Freisen
| Companies | Position | End |
|---|---|---|
| ABLYNX | Chief Tech/Sci/R&D Officer | 2018-12-31 |
| PROQR THERAPEUTICS N.V. | Corporate Officer/Principal | 2017-12-31 |
| Janssen Biotherapeutics | Corporate Officer/Principal | 2013-12-31 |
| MORPHOSYS AG | Corporate Officer/Principal | - |
Training of Robert Freisen
| The University of Texas at Austin | Doctorate Degree |
| University of Utrecht | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MORPHOSYS AG | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
| Janssen Biotherapeutics |
- Stock Market
- Insiders
- Robert Freisen
